Thr287-Gly550, with C-terminal Human IgG1 Fc TMKKKVKLKMVTPRPASTRVPKVNLPYSSEEGVSRGRNYDGEQKKKEEGKRERLEEEKGEKTLRNEVEQERTLRGDVFSPKVNEAEDLDLVYVQRKELNSKLKHKDLNISVDCSFDLGVCDWKQDREDDFDWHPADRDNDVGYYMAVPALAGHKKNIGRLKLLLPNLTPQSNFCLLFDYRLAGDKVGKLRVFVKNSNNALAWEETKNEDGRWRTGKIQLYQGIDTTKSVIFEAERGKGKTGEIAVDGVLLVSGLCPDDFLSVEGIEGRMDPKSSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
1. An, J., Du, Y., Fan, X. et al. EGFL6 promotes breast cancer by simultaneously enhancing cancer cell metastasis and stimulating tumor angiogenesis. Oncogene 38, 2123-2134 (2019). https://doi.org/10.1038/s41388-018-0565-9.
EGFL6, a member of the EGF-like superfamily, plays an important role during embryonic development and has been implicated in promotion of tumor angiogenesis without affecting wound healing. Importantly, expression of EGFL6 in cancer cells and tumor endothelial cells not only increased tumor angiogenesis but also promoted migration of cancer cells. Members of this superfamily are characterized by the presence of EGF-like repeats and are often involved in the regulation of cell cycle, proliferation, and developmental processes. EGFL6 gene is expressed early during development, and its expression has been detected in lung and meningioma tumors.
1μg (R: reducing conditions, N: non-reducing conditions).
您现在的位置：